##semicolon##
metabolik assotsiatsiyalangan jigar yog‘ kasalligi, MASLD, surunkali buyrak kasalligi, kardiometabolik xavf, insulinrezistentlik, yallig‘lanish, oksidlovchi stress, endotelial disfunksiya, FIB-4, eGFR, albuminuriya, biomarkerlar.##submission.citations##
1. Rinella M.E., Lazarus J.V., Ratziu V., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature // Hepatology. 2023. Vol. 78, No. 6. P. 1966–1986. DOI: 10.1097/ HEP.0000000000000520.
2. European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) // Journal of Hepatology. 2024. Vol. 81, No. 3. P. 492–542. DOI: 10.1016/j.jhep.2024.04.031.
3. Kueh C.Y., et al. Global prevalence, incidence, and outcomes of coexisting MASLD and chronic kidney disease: a meta-analysis // Liver International. 2026. DOI: 10.1111/liv.70747.
4. Sumida K., Kovesdy C.P. Emerging cardiovascular risk factors in chronic kidney disease in the “omics” era: gut and beyond // Mayo Clinic Proceedings. 2026. Vol. 101, No. 4. P. 648–662.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease // Kidney International. 2024. Vol. 105, Suppl. 4S. P. S117–S314. DOI: 10.1016/j.kint.2023.10.018.
6. Ndumele C.E., Neeland I.J., Tuttle K.R., et al. Cardiovascular-Kidney-Metabolic Health: a Presidential Advisory from the American Heart Association // Circulation. 2023. Vol. 148, No. 20. P. 1606–1635. DOI: 10.1161/CIR.0000000000001184.
7. Spoto B., Pisano A., Zoccali C. Insulin resistance in chronic kidney disease: a systematic review // American Journal of Physiology-Renal Physiology. 2016. Vol. 311, No. 6. P. F1087–F1108. DOI: 10.1152/ajprenal.00340.2016.
8. Chmielewski M., Carrero J.J., Stenvinkel P., Lindholm B. Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease // Current Opinion in Lipidology. 2009. Vol. 20, No. 1. P. 3–9.
9. Li Y., Zhong X., Cheng G., et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis // Atherosclerosis. 2017. Vol. 259. P. 75–82. DOI: 10.1016/j.atherosclerosis.2017.02.003.
10. Meng X.M., Nikolic-Paterson D.J., Lan H.Y. TGF-β: the master regulator of fibrosis // Nature Reviews Nephrology. 2016. Vol. 12, No. 6. P. 325–338. DOI: 10.1038/nrneph.2016.48.
11. Rutherford E., Mark P.B. What happens to the heart in chronic kidney disease? // Journal of the Royal College of Physicians of Edinburgh. 2017. Vol. 47, No. 1. P. 76–82.
12. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. 2023. Vol. 77, No. 5. P. 1797–1835. DOI: 10.1097/HEP.0000000000000 323.
13. Canadian Association of Radiologists Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group. Part 2: Recommendations for risk stratifying patients with MASLD // Canadian Association of Radiologists Journal. 2025. DOI: 10. 1177/08465371251357447.
14. Hageman S.H.J., Pennells L., Ojeda F., et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe // European Heart Journal. 2021. Vol. 42, No. 25. P. 2439–2454. DOI: 10.1093/eurheartj/ehab309.